Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
22,258
Total Claims
$1.3M
Drug Cost
680
Beneficiaries
$1,971
Cost/Patient
Risk Score Breakdown 12/100
Score components are additive. Read full methodology
Peer Comparison vs. 7,389 General Practice providers
-98%
Opioid rate vs peers
0.0% vs 2.5% avg
+75%
Cost per patient vs peers
$1,971 vs $1,128 avg
+40%
Brand preference vs peers
11.8% vs 8.4% avg
Brand vs Generic
Brand: 2,580 claims · $1.1M
Generic: 19,345 claims · $248K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Sitagliptin Phosphate | 158 | $129K |
| Insulin Glargine,hum.Rec.Anlog | 261 | $100K |
| Rivaroxaban | 118 | $90K |
| Empagliflozin | 101 | $90K |
| Dulaglutide | 81 | $77K |
| Linaclotide | 86 | $54K |
| Levothyroxine Sodium | 588 | $53K |
| Apixaban | 83 | $48K |
| Dapagliflozin Propanediol | 41 | $36K |
| Linagliptin | 37 | $29K |
| Insulin Lispro | 53 | $26K |
| Sitagliptin Phos/Metformin Hcl | 20 | $24K |
| Insulin Nph Human Isophane | 97 | $21K |
| Insulin Nph Hum/Reg Insulin Hm | 51 | $17K |
| Rivastigmine | 23 | $16K |
Prescribing Profile
Patient Profile
71
Avg Age
53%
Female
1.55
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data